Fatigue Mental fatigue in moderate‐grade hepatic encephalopathy Wessely and Powell test Scale from 0 to 10 · patients with covert or overt hepatic encephalopathy
1 finding from 1 review
Non‐serious adverse events · patients with covert or overt hepatic encephalopathy
It is very uncertain whether acetyl‐L‐carnitine changes non‐serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Number of days in hospital (duration of hospitalisation) · patients with covert or overt hepatic encephalopathy
1 finding from 1 review
Blood ammonium levels · patients with covert or overt hepatic encephalopathy
1 finding from 1 review
All‐cause mortality: at 3 years · primary hepatocellular carcinoma
TACE followed by 3‐DCRT may leads to lower all‐cause mortality: at 3 years compared with TACE (low certainty).
1 finding from 1 review
Proportion of participants without tumour response (CR+PR) · primary hepatocellular carcinoma
TACE followed by 3‐DCRT may leads to lower proportion of participants without tumour response (CR+PR) compared with TACE (low certainty).
1 finding from 1 review
Serious adverse events · primary hepatocellular carcinoma
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Health‐related quality of life · primary hepatocellular carcinoma
1 finding from 1 review
Non‐serious adverse events: leukopenia · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).
1 finding from 1 review
Non‐serious adverse events: serum transaminases elevation · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: serum transaminases elevation compared with TACE (very low certainty).
1 finding from 1 review
Non‐serious adverse events: total bilirubin elevation · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: total bilirubin elevation compared with TACE (very low certainty).
1 finding from 1 review
Proportion of participants without serum AFP normalisation · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes proportion of participants without serum AFP normalisation compared with TACE (very low certainty).
1 finding from 1 review
All‐cause mortality · adults with cirrhosis and hepatic encephalopathy
1 finding from 1 review
Blood ammonia concentrations (units unspecified) · adults with cirrhosis and hepatic encephalopathy
3 findings from 1 review
no estimate extracted
1 study · 35 participants
Very low
no estimate extracted
1 study · 16 participants
Very low
no estimate extracted
1 study · 231 participants
Very low
Blood ammonia concentrations (µmol/L*week) · adults with cirrhosis and hepatic encephalopathy
2 findings from 1 review
Hepatic encephalopathy · adults with cirrhosis and hepatic encephalopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with cirrhosis and hepatic encephalopathy
1 finding from 1 review
Non‐serious adverse events · adults with cirrhosis and hepatic encephalopathy
1 finding from 1 review
Health‐related quality of life · adults with cirrhosis and hepatic encephalopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Plasma ammonia concentration (µmol/L) · adults with cirrhosis and hepatic encephalopathy
1 finding from 1 review